Palliative care 2016

Phase II or retrospec+ve cohorts

Author/year

Design # mCRC pts. Lung/liver/LN Fract x dose

Local control 2 years

Survival 2 years

3 x 9.2-­‐20Gy (NTCP-­‐based)

Lee 2009

Phase I

40/68

0/40/0

(-­‐)

35%

Van der Pool 2010 Phase I/II

20

0/20/0

3 x 12.5Gy

74%

83%

Kang 2010

Retrospect

59

13/10/31

3 x 12-­‐17Gy

65%

65%

Chang 2011

Phase I/II

65 41

0/65/0

1x22-­‐3x20 Gy 3 x 15-­‐20 Gy

55% 76%

38% 68%

Bae 2012

Retrospect

12/11/18

Van den Begin 2014

4-­‐5 x 10 Gy (isocenter)

53%(lung/liver) 79% (LN) 1-­‐year

Retrospect

47

NA

65%*

Retrospect mCRC: Local control rates 31-­‐85% 40 82 40/0/0 1 x 26-­‐4 x 12 Gy 4 x 12-­‐3 x 25Gy NA Phase II 60/52/0

Filippi 2014

73% 65%

Comito 2014 Thibault 2014

80% 76% 33%

Retrospect Retrospect

45/83

4 x 12-­‐20 Gy

72%*

De Vin 2014

103/309

56/77/176

10 x 4-­‐5 Gy

32% (3-­‐year)

Takahachi 2014 Carbon ions

Feasibility

34

34/0/0

4 x 13.2-­‐15 GyE

85%

65%

Qiu 2015

Retrospect

64

42/NA/NA 10x5Gy or 5x10Gy

31%

43%

3 x 15-­‐22.5 Gy (isocenter)

Fode 2015

Retrospect

201

30/165/6

LR: 13%

58%